Multiple Sclerosis Drugs - Malaysia

In Malaysia, the Multiple Sclerosis Drugs market is anticipated to achieve a revenue of US$28.67m in 2024.
This indicates an expected annual growth rate (CAGR 2024-2029) of 1.70%, leading to a market volume of US$31.20m by 2029.
When compared globally, United States is expected to generate the highest revenue of US$11.77bn in 2024.
Malaysia's demand for Multiple Sclerosis Drugs is steadily increasing, driven by a growing awareness and diagnosis of the disease.

Definition:
This market covers drugs to treat the neurological autoimmune disease multiple sclerosis. As there is no cure for multiple sclerosis, the goal is to improve functions after an attack or to prevent attacks. Different types of medication include immunomodulators, immunosuppressants, and interferons. Monoclonal antibodies are now being increasingly used.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Biogen, Roche, Novartis, Sanofi

Drugs to treat multiple sclerosis
Monoclonal antibodies
Immunosuppressants

Monoclonal antibodies and immunosuppressants for the treatment of other diseases
Treatment of other autoimmune diseases
Alternative medicine

The Multiple Sclerosis Drugs market in Malaysia has been steadily growing in recent years.

Customer preferences: Patients with Multiple Sclerosis in Malaysia prefer drugs that are affordable, effective, and have minimal side effects. They also prefer drugs that are easily accessible and can be obtained without much hassle.

Trends in the market: The Multiple Sclerosis Drugs market in Malaysia has been driven by the increasing prevalence of the disease in the country. The rising awareness about the disease and the availability of effective treatment options have also contributed to the growth of the market. Additionally, the government's efforts to improve healthcare infrastructure and increase healthcare spending have also played a significant role in the growth of the market.

Local special circumstances: Malaysia has a diverse population with varying healthcare needs. The country's healthcare system is also fragmented, with both private and public healthcare providers. This has led to differences in the availability and accessibility of Multiple Sclerosis drugs across different regions of the country.

Underlying macroeconomic factors: The Malaysian economy has been growing steadily in recent years, which has led to an increase in disposable income and healthcare spending. The government's efforts to improve healthcare infrastructure and increase healthcare spending have also contributed to the growth of the Multiple Sclerosis Drugs market in the country. Additionally, the country's strategic location and favorable business environment have made it an attractive destination for pharmaceutical companies looking to expand their operations in the region.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.